Clinical Design and Objectives

This study is an open‑label, multi‑center Phase 1b trial evaluating dose exploration of CX‑5461 administered intravenously on Day 1 and Day 8 of a 28‑day cycle. The primary objectives are to assess safety and tolerability and to identify the recommended dose for subsequent Phase 2 studies. Secondary objectives include evaluation of preliminary anti‑tumor activity and changes in health‑related quality of life (HRQoL).

Population and Biomarkers

Eligible participants are solid‑tumor patients harboring BRCA1/2, PALB2 mutations or homologous recombination deficiency (HRD) alterations. These genetic lesions confer DNA repair defects that may render tumors sensitive to DNA‑damage‑inducing agents such as CX‑5461. The trial will explore mutational signatures, circulating tumor DNA (ctDNA) dynamics, and plasma DNA methylation profiling within an exploratory cohort.

Differentiation and Expected Benefits

CX‑5461 is an RNA polymerase I transcription inhibitor that selectively induces DNA damage in HRD‑positive cancer cells, leading to apoptosis. Its mechanism of action differs from that of existing PARP inhibitors, offering a potential alternative in the setting of PARP resistance. Biomarker‑driven patient selection enables validation of a precision‑medicine therapeutic strategy, distinguishing this program.

Market and Clinical Impact

Cancers with HRD alterations affect millions of patients worldwide, with particularly high prevalence in breast, ovarian, and prostate cancers. If CX‑5461 demonstrates safety and efficacy, it could deliver a differentiated portfolio relative to existing PARP inhibitors and generate partnership or M&A opportunities. This would provide a new growth engine for biopharma companies and investors alike.